CommercialCoverageMedium impact
Bortezomib (Velcade®; Bortezomib, Boruzu™)
BCBS Tennessee·TN · Oncology, Hematology·Medical Policy
Effective date
Jul 31, 2026
We identified it
Jun 17, 2026
Summary
BlueCross BlueShield of Tennessee is implementing a new medical policy for bortezomib (Velcade, Boruzu) covering multiple cancer conditions and other specified indications. The policy establishes coverage criteria, dosing limits, and 12-month authorization periods for various oncologic and hematologic conditions.
Action Required
Before July 31, 2026: Review current bortezomib prescriptions and ensure they align with the new coverage criteria. Update prior authorization workflows to reflect 12-month authorization periods for covered indications including multiple myeloma, mantle cell lymphoma, and other specified conditions. Verify dosing does not exceed 1.6 mg/m2 per dose or 7 doses per 30-day period. Train clinical staff on the expanded list of covered compendial uses.